Korean J Head Neck Oncol Search


Korean Journal of Head & Neck Oncology 2005;21(2):126-131.
Published online November 30, 2005.
Docetaxel and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Cancer
Eun Hee Cho;Keun Hyok Cho;Young Bong Song;Ik Sung Choi;Jae Won Choi;Seung Hyun Nam;Bong Seog Kim
국소 진행성 두경부암 환자에서의 Docetaxel과 Cisplatin 유도화학요법
Objectives: To evaluate the efficacy and safety of induction chemotherapy with docetaxel and cisplatin in locally advanced head and neck cancer. Materials and Methods: Between June 1998 and December 2004, 30 patients were enrolled and among them, 20 patients were evaluable. Patients were treated with docetaxel 75mg/m² and cisplatin 60mg/m² on day 1 every 21 days.
The median age was 71(range 54-80) years old. All 20 patients were male. Nineteen patients had pathologically squamous cell carcinoma and 1 had undifferentiated carcinoma. Fourteen of 20 patients(70%) demonstrated an objective response with two(10%) achieving a complete clinical response and eleven(60%) a partial response. The median response duration was 5.3(1.6-32.1) months and the median time to progression was 5.6(1.4-33.8) months. The median overall survival of all patients was 14(range 2.2-34) months. The median overall survival of responders was 17.5(range 5-34) months and that of non-responders was 3.2(range 2.2-23) months, but it was not statistically significant(p=0.106). During a total of 92 cycles, granulocytopenia worse than CTC(Common toxicity criteria) grade 2 occurred in 6%, thrombocytopenia in 2%, and anemia in 3%, respectively. Non-hematologic toxicities were minor and easily controlled.
The induction chemotherapy of docetaxel and cisplatin has moderate efficacy with acceptable toxicities in patients with locally advanced head and neck cancer.
Key Words: Head and neck cancer, Docetaxel, Cisplatin


Browse all articles >

Editorial Office
327, Sosa-ro, Bucheon-si, Gyeonggi-do 14647, Korea
Tel: +82-10-9810-7671    Fax: +82-504-223-7671    E-mail: kshno@hanmail.net                

Copyright © 2024 by Korean Society for Head & Neck Oncology.

Developed in M2PI

Close layer
prev next